XSHG
600479
Market cap891mUSD
Oct 09, Last price
12.44CNY
1D
2.56%
1Q
30.26%
Jan 2017
-5.33%
IPO
167.53%
Name
ZhuZhou QianJin Pharmaceutical Co Ltd
Chart & performance
P/E
21.39
P/S
1.68
EPS
0.58
Div yield, %
2.97%
Shrs. gr., 5y
1.40%
Rev. gr., 5y
0.04%
Revenues
3.63b
+0.13%
Net income
286m
+24.07%
CFO
480m
+20.43%
Dividend
Jun 30, 20260.38 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1993 and headquartered in Zhuzhou, China, ZhuZhou QianJin Pharmaceutical Co.,Ltd operates as a leading manufacturer and distributor of pharmaceutical goods throughout China. The company boasts a comprehensive product portfolio, encompassing treatments for women's health, pediatric ailments, dermatological concerns, anti-infectives, and conditions affecting the circulatory, endocrine, digestive, nervous, and cardiovascular systems. Additionally, they offer specialized medications and traditional Chinese remedies. These diverse pharmaceutical offerings are presented in various formats, including pills, tablets, capsules, granules, powders, decoctions, and liquid solutions. Beyond its core pharmaceutical business, ZhuZhou QianJin also produces ginger-based beverages, feminine hygiene products, and alcoholic beverages.
Key people
Duanyu Jiang
Chairman of the Board · since 2015
Shun Jian
General Manager · since 2015
Fujun Li
Deputy General Manager · since 2011
Jianwu Liu
Deputy General Manager · since 2011
Aiwei Xie
Chief Financial Officer, Finance Director, Deputy General Manager, Secretary of the Board · since 2013
Tiesheng Liao
Director · since 2010
Chao Xie
Director · since 2008
Independent Director · since 2008
Zhaoling You
Independent Director · since 2011
Independent Director · since 2008
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||